- Current report filing (8-K)

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

March 5, 2009

Date of Report
(Date of earliest event reported)

MIDDLEBROOK PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware		000-50414		52-2208264
(State or Other		(Commission File Number)		(IRS Employer
Jurisdiction of				Identification No.)
Incorporation)

7 Village Circle, Suite 100, Westlake, Texas 76262

(Address of Principal Executive Offices) (ZIP Code)

Registrant’s telephone number, including area code: [phone]

20425 Seneca Meadows Parkway, Germantown, Maryland 20876

Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

 

 

 

---

 

Item 2.02. Results of Operations and Financial Condition.

     On March 5, 2009, MiddleBrook Pharmaceuticals, Inc. issued a press release announcing its financial and operational results for the quarter and year ended December 31, 2008. A copy of the release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 — Financial Statements and Exhibits.

     (d) Exhibits

Exhibit		Description
99.1		Press Release issued March 5, 2009

2

---

 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MIDDLEBROOK PHARMACEUTICALS, INC.
Date: March 5, 2009	By:	/s/ Dave Becker
		Dave Becker
		Executive Vice President and Chief Financial Officer

3

---

 

INDEX TO EXHIBITS

Exhibit		Description
99.1		Press Release issued March 5, 2009

4